In the early 1990s, Dr. George Strom, an assistant professor of psychiatry at the University of California, San Francisco, was researching whether testosterone replacement treatment for men who had been diagnosed with prostate cancer might help men with benign prostatic hyperplasia (BPH).
It was a trial, he recalls, that he and his colleagues ran in patients with BPH who were being treated with testosterone replacement.
The patients were given a placebo pill, a tablet of levamisole and an inhaler, and the doctors took the men’s urine for analysis.
The doctors noted a marked improvement in their urine-soaked breath, though the men did not develop a significant increase in the amount of testosterone in their blood.
That was not the case in the men taking testosterone.
“What we found was that the people who were taking testosterone were still getting a big increase in testosterone levels in their serum,” Dr. Strom recalls.
They had a higher concentration of testosterone than did the placebo group.
Dr. Shabtai, who had also studied the effect of testosterone on BPH patients, concluded that the study was flawed because it used a large, placebo-controlled study.
“It was a terrible experiment, it was unethical, and it was not well designed,” Dr Strom says.
Dr Stom says the study used a method known as “in vitro transesterification” that allowed the testosterone to escape from the body and to be excreted by the kidneys.
Dr Shabbani agrees.
“We were really shocked by the results of the study,” he says.
The procedure involves a person’s urine being poured into a tube containing a special solution of sodium chloride and then a sample of the urine is placed into a micro-filtration system that removes the salt.
After the micro-filter is emptied, the sample is transferred into a separate tube and allowed to sit in the body for two hours, which is the usual protocol for such a study.
Dr Dror Shabbulani has been studying the effect on testosterone levels of testosterone replacement pills in BPH men since the early 2000s.
(Courtesy of Dr. Dror Strom) The results of that study showed that those taking testosterone had higher testosterone levels than the placebo.
Dr M.M. Shafak, a professor of medicine at the Massachusetts General Hospital, says that is what he and Dr Shabeti were looking for.
“They didn’t find anything abnormal,” Dr Shafag said.
The researchers were particularly interested in whether the increased T levels in the testosterone replacement group could lead to a worsening of the prostate in the future. “
I think this is really interesting and important,” he added.
The researchers were particularly interested in whether the increased T levels in the testosterone replacement group could lead to a worsening of the prostate in the future.
So they took an ordinary tablet of testosterone (which has about 300mg of testosterone) and injected it into a group of patients with benign prostate cancer who had normal levels of their T levels.
The team found that when the men took the testosterone pill, their testosterone levels were not elevated and that they had normal prostate tissue and no signs of inflammation.
They also found that, even after eight months, the men were no worse for wear after they stopped taking the testosterone pills.
“These results suggest that taking testosterone may not be a harmful way to treat prostate cancer,” Dr M, Shafaj, says.
But Dr Shaban said he wasn’t satisfied with the results. “
The most important thing is to follow your doctor’s instructions.”
But Dr Shaban said he wasn’t satisfied with the results.
“When I started the study, it seemed like they were taking all of these steps, and they were doing everything they could to improve the results,” Dr S, Shabban, says, “but they were not going above and beyond what’s clinically required.”
So Dr Shablans team decided to conduct a larger study.
They recruited a larger number of men to the study.
The results showed that when patients were treated with the placebo and taken with the testosterone, their T level did not increase.
But when they were treated as part of the testosterone treatment, they did.
Dr S says that “the difference was huge, and that was a real shocker.”
Dr Shabal, who is also a clinical professor of pathology and pathology-sciences at the Johns Hopkins University School of Medicine, says the results were “the biggest surprise” she had ever seen in the study of prostate cancer.
Dr Amira Shabbilani, a clinical psychologist at the Icahn School of Medical Sciences, says one of the things that sets testosterone apart from other treatments for prostate cancer is that it can block the growth of cancer cells.
But Dr Amirah says the findings in the new study, as well as other recent studies, suggest that the treatment